Fact-checking Trump’s address to Congress
President Donald Trump made numerous false claims in his Tuesday speech to a joint session of Congress. The falsehoods ...
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...
Fourth quarter 2024 results: EUR 233 million net income in Q4 2024 Proposed regular dividend of EUR 1.8 per share
The annualized Return on Equity stands at 22.8% (23.0% adjusted 1) in Q4 2024.